<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501341</url>
  </required_header>
  <id_info>
    <org_study_id>132/PT02.FK25/U.Eu113/METEND/V</org_study_id>
    <nct_id>NCT04501341</nct_id>
  </id_info>
  <brief_title>BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>Effectivity and Safety of Autologous BM-MNC Stem Cell Therapy and Allogenic Umbilical Cord Mesenchymal Stem Cell for Type 2 Diabetes Mellitus Patients&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr Cipto Mangunkusumo General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this preliminary study is to evaluate the safety and efficacy of bone-marrow&#xD;
      mononuclear cells (BM-MNCs) and umbilical-cord tissue-derived mesenchymal stem cells&#xD;
      (UC-MSCs) administration in type 2 diabetes patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes (T2D) patients had peripheral insulin resistance accompanied by progressive&#xD;
      pancreatic beta cell degeneration and dysfunction due to glucotoxicity and lipotoxicity.&#xD;
      Several studies have shown that the immune system plays a significant role in the&#xD;
      pathogenesis of T2D. Bone-marrow mononuclear cells (BM-MNCs) and umbilical-cord&#xD;
      tissue-derived mesenchymal stem cells (UC-MSCs) via its immunomodulatory properties have the&#xD;
      potential to improve insulin resistance condition and pancreatic beta-cells dysfunction thus&#xD;
      improve the glycemic control and insulin requirement in T2D patients. In this pilot study, we&#xD;
      plan to recruit 15 T2D patients with total daily dose of insulin &gt;= 0.5 unit/kgBW/day to&#xD;
      receive BM-MNCs (5 subjects) or UC-MSCs injections (10 subjects). These subjects will be&#xD;
      closely followed up for 12 months for evaluation of primary and secondary outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>5 subjects receive BM-MNC and 10 subjects receive UC-MSC</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreasing total daily dose of insulin (&gt;= 30%)</measure>
    <time_frame>Before intervention, 1st, 3rd, 6th, and 12th month after intervention</time_frame>
    <description>After intervention, blood glucose level will be reported by the subjects on weekly basis. The insulin dose and/or oral medication will be adjusted accordingly.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increasing of C-peptide level</measure>
    <time_frame>Before intervention, 1st, 3rd, 6th, and 12th month after intervention</time_frame>
    <description>Measurements were obtained with mixed meal tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreasing of insulin resistance level</measure>
    <time_frame>Before intervention, 1st, 3rd, 6th, and 12th month after intervention</time_frame>
    <description>Measurement of HOMA-IR, calculated using fasting C-peptide and fasting plasma glucose formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology/inflammatory markers</measure>
    <time_frame>Before intervention, 1st, 3rd, 6th, and 12th month after intervention</time_frame>
    <description>Measurements of Interleukin-10 and TNF-alfa from serum and supernatant from PBMC stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 12 months after intervention</time_frame>
    <description>Thrombosis, hemorrhage, and infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Before intervention, 1st, 3rd, 6th, and 12th month after intervention</time_frame>
    <description>Stable HbA1c or decreasing HbA1c (from baseline)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>T2D</condition>
  <arm_group>
    <arm_group_label>BM-MNC experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologue bone marrow mononuclear cell</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UC-MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical cord mesenchymal stem cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC</intervention_name>
    <description>Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas according to the results of previous pancreatic CT-scan, performed by interventional radiologist. The target is to distribute the BM-MNCs equally in all part of the pancreas. Dosage: 1 x 10^5 - 1 x 10^6 CD34 cells/kgBW</description>
    <arm_group_label>BM-MNC experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous Infusion of UC-MSC</intervention_name>
    <description>Allogeneic umbilical cord tissue-derived mesenchymal stem cells will be given via intravenous infusion. Dosage: 2 x 10^6 cells/kgBW, twice, with three months interval</description>
    <arm_group_label>UC-MSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes patients on insulin therapy with or without oral hypoglycemic agents,&#xD;
             with total daily dose of insulin &gt;= 0,5 unit/kg body weight&#xD;
&#xD;
          -  Stable HbA1C in the last six months (HbA1c &lt;= 8.5%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  eGFR &lt; 45 mL/min/m2 (for BM-MNC)&#xD;
&#xD;
          -  Liver disease (moderate- severe)&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Contrast hypersensitivity (for BM-MNC)&#xD;
&#xD;
          -  History of Malignancy&#xD;
&#xD;
          -  Acute coronary syndrome in last three months&#xD;
&#xD;
          -  Coronary arterial diseases with significant stenosis and has not carried out&#xD;
             revascularization&#xD;
&#xD;
          -  Pregnancy (for women subjects)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine, Universitas Indonesia</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pradana Soewondo, Prof</last_name>
      <phone>+628188160756</phone>
      <email>pradana.soewondo@ui.ac.id</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Itariu BK, Stulnig TM. Autoimmune aspects of type 2 diabetes mellitus - a mini-review. Gerontology. 2014;60(3):189-96. doi: 10.1159/000356747. Epub 2014 Jan 22. Review.</citation>
    <PMID>24457898</PMID>
  </reference>
  <reference>
    <citation>Tsai S, Clemente-Casares X, Revelo XS, Winer S, Winer DA. Are obesity-related insulin resistance and type 2 diabetes autoimmune diseases? Diabetes. 2015 Jun;64(6):1886-97. doi: 10.2337/db14-1488. Review.</citation>
    <PMID>25999531</PMID>
  </reference>
  <reference>
    <citation>Campbell RK, Martin TM. The chronic burden of diabetes. Am J Manag Care. 2009 Sep;15(9 Suppl):S248-54.</citation>
    <PMID>19817513</PMID>
  </reference>
  <reference>
    <citation>FÃ©ry F, Paquot N. [Etiopathogenesis and pathophysiology of type 2 diabetes]. Rev Med Liege. 2005 May-Jun;60(5-6):361-8. Review. French.</citation>
    <PMID>16035295</PMID>
  </reference>
  <reference>
    <citation>Wehbe T, Chahine NA, Sissi S, Abou-Joaude I, Chalhoub L. Bone marrow derived stem cell therapy for type 2 diabetes mellitus. Stem Cell Investig. 2016 Dec 6;3:87. doi: 10.21037/sci.2016.11.14. eCollection 2016.</citation>
    <PMID>28066789</PMID>
  </reference>
  <reference>
    <citation>Guan LX, Guan H, Li HB, Ren CA, Liu L, Chu JJ, Dai LJ. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Exp Ther Med. 2015 May;9(5):1623-1630. Epub 2015 Mar 9.</citation>
    <PMID>26136869</PMID>
  </reference>
  <reference>
    <citation>Estrada EJ, Valacchi F, Nicora E, Brieva S, Esteve C, Echevarria L, Froud T, Bernetti K, Cayetano SM, Velazquez O, Alejandro R, Ricordi C. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant. 2008;17(12):1295-304.</citation>
    <PMID>19364067</PMID>
  </reference>
  <reference>
    <citation>Bhansali A, Asokumar P, Walia R, Bhansali S, Gupta V, Jain A, Sachdeva N, Sharma RR, Marwaha N, Khandelwal N. Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplant. 2014;23(9):1075-85.</citation>
    <PMID>23561959</PMID>
  </reference>
  <reference>
    <citation>Hu J, Li C, Wang L, Zhang X, Zhang M, Gao H, Yu X, Wang F, Zhao W, Yan S, Wang Y. Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus. Endocr J. 2012;59(11):1031-9. Epub 2012 Jul 13.</citation>
    <PMID>22814142</PMID>
  </reference>
  <reference>
    <citation>Chao YH, Wu HP, Chan CK, Tsai C, Peng CT, Wu KH. Umbilical cord-derived mesenchymal stem cells for hematopoietic stem cell transplantation. J Biomed Biotechnol. 2012;2012:759503. doi: 10.1155/2012/759503. Epub 2012 Oct 3. Review.</citation>
    <PMID>23093863</PMID>
  </reference>
  <results_reference>
    <citation>Weiss ARR, Dahlke MH. Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. Front Immunol. 2019 Jun 4;10:1191. doi: 10.3389/fimmu.2019.01191. eCollection 2019. Review.</citation>
    <PMID>31214172</PMID>
  </results_reference>
  <results_reference>
    <citation>Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Fu QL, Lian Q. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016 Jan 21;7:e2062. doi: 10.1038/cddis.2015.327. Review.</citation>
    <PMID>26794657</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>August 2, 2020</last_update_submitted>
  <last_update_submitted_qc>August 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fakultas Kedokteran Universitas Indonesia</investigator_affiliation>
    <investigator_full_name>Prof. Dr. dr. Pradana Soewondo, SpPD-KEMD</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>Bone-marrow mononuclear cells</keyword>
  <keyword>Umbilical cord mesenchymal stem cells</keyword>
  <keyword>Glycemic control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

